Actively Recruiting
Mechanisms for Activation of Beige Adipose Tissue in Humans
Led by Philip Kern · Updated on 2026-02-03
65
Participants Needed
1
Research Sites
312 weeks
Total Duration
On this page
Sponsors
P
Philip Kern
Lead Sponsor
N
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Mirabegron (Myrbetriq®, Astellas) is a highly specific and well-tolerated ß3 agonist marketed for overactive bladder. This trial will assess the effects of mirabegron on glucose tolerance and adipose tissue in prediabetic patients
CONDITIONS
Official Title
Mechanisms for Activation of Beige Adipose Tissue in Humans
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Body mass index (BMI) between 27 and 45
- Diagnosis of prediabetes with A1c between 5.7 and 6.4
- Presence of impaired fasting glucose or impaired glucose tolerance
You will not qualify if you...
- Diagnosis of diabetes
- Chronic use of anti-diabetic medication
- Acute or chronic inflammatory conditions
- Unstable medical conditions
- Cancer
- Kidney (renal) insufficiency
- Any contraindication for Mirabegron
- Body mass index (BMI) over 45
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Kentucky
Lexington, Kentucky, United States, 40536
Actively Recruiting
Research Team
Z
Zach Leicht
CONTACT
P
Philip Kern, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here